Search Results
Feb 03, 2026, 16:01 ET AMGEN REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS
relapsed or refractory CD19-positive Philadelphia chromosome (Ph) negative B-cell precursor acute lymphoblastic leukemia (B-ALL).Golden Gate, a Phase 3 study of BLINCYTO alternating with low-intensity chemotherapy, is enrolling older adult patients with newly diagnosed CD19-positive Ph-negative
More news about: Amgen
Feb 03, 2026, 08:00 ET AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Adults and Adolescents With Vitiligo
or pill (systemic therapy) when your healthcare provider does not recommend TNF blockers.Adults with moderate to severe Crohn's disease (CD) when 1 or more medicines called TNF blockers have been used and did not work well or could not be tolerated, or after taking a different injection
More news about: AbbVie
Feb 03, 2026, 04:31 ET Biosion Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial of BSI-082, a Next-Generation Anti-SIRPα Monoclonal Antibody for Advanced Solid Tumors
with Aclaris Therapeutics for its immunology portfolio.Collaborating to Unlock Innate ImmunityBSI-082 is engineered to block the CD47-SIRPα "don't eat me" signal, a critical checkpoint tumor cells use to evade macrophage phagocytosis. Unlike other candidates in the class, BSI-082
More news about: Biosion, Inc.
Feb 02, 2026, 17:31 ET TIGIT Inhibitors Market Poised for Strong Growth Through 2034, Driven by Expanding Immuno-Oncology Pipeline | DelveInsight
monoclonal antibody directed against the immune checkpoint receptor TIGIT. By preventing TIGIT from binding to its ligands CD112 and CD155, it augments CD226-driven signaling in NK cells and CD8⁺ T cells, leading to enhanced anti-tumor immune activity. Domvanalimab is currently being investigated in non-small
More news about: DelveInsight Business Research, LLP
Feb 02, 2026, 16:05 ET ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl).ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed
More news about: ADC Therapeutics SA
Feb 02, 2026, 11:00 ET InsCorp, Inc. Reports Results for 4Q25 and 2025
interest-bearing demand, and money market balances increased 39% Y/Y lifting the mix to 46% of deposits compared to 42% a quarter ago and 39% a year ago. CD balances grew 7% Y/Y in 2025 and decreased to 54% of deposits versus 58% a quarter ago and 61% a year ago. INSBANK ended the year with a loan-to-deposit
More news about: INSBANK
Feb 02, 2026, 09:58 ET DataOps.live's John Marchese Recognized as a 2026 CRN® Channel Chief
pipeline automation. This resulted in a PLG Marketplace Launch of DataOps.live's Dynamic Suite, featuring Snowflake Native Apps designed to automate CI/CD and dbt™ transformations directly within the Snowflake AI Data Cloud.Major Customer Use Case and Expansion: As commercial lead for the
More news about: DataOps.live
Feb 02, 2026, 09:17 ET Medtronic Diabetes expands access to full-stack insulin delivery solutions with Medicare access and new FDA clearances
How Fast Is Really Needed?. Clin Diabetes 1 October 2021; 39 (4): 415–423. https://doi.org/10.2337/cd20-0119§ Refers to SmartGuard™ feature. Individual results may varyThe sensor shape and appearance, Abbott, and
More news about: Medtronic plc
Feb 02, 2026, 09:15 ET Columbus McKinnon Receives Clearance from the DOJ for Pending Acquisition of Kito Crosby
agreement relating to each of the Acquisition and the Divestiture, (6) the dilution caused by the issuance of perpetual convertible preferred equity to CD&R, (7) the possibility that the Acquisition or the Divestiture may be more expensive to complete than anticipated, including as a result of unexpected
More news about: Columbus McKinnon Corporation
Feb 02, 2026, 02:16 ET Xinhua Silk Road: Ökosystem und Nachhaltigkeit definieren den Wert einer globalen Automobilmarke neu: Bericht
https://mma.prnewswire.com/media/2874305/8b40cd644d6640d19b49330065ddd022.jpg
More news about: Xinhua Silk Road
Feb 01, 2026, 20:44 ET Xinhua Silk Road: Ecosystem and sustainability redefine global automotive brand value: report
https://mma.prnewswire.com/media/2874305/8b40cd644d6640d19b49330065ddd022.jpg
More news about: Xinhua Silk Road
Jan 30, 2026, 18:44 ET PEOPLES FINANCIAL SERVICES CORP. Reports Unaudited Fourth Quarter and Full Year 2025 Earnings
31, 2025, and December 31, 2024, respectively. As part of strategic balance sheet management initiatives, the Company reduced its higher rate brokered CD portfolio by $104.2 million during 2025. Total retail deposits, which exclude brokered deposits, increased $130.7 million to $4.3 billion at December
More news about: Peoples Financial Services Corp.
Jan 30, 2026, 17:00 ET BANKFIRST CAPITAL CORPORATION Reports Fourth Quarter and Year-End 2025 Earnings of $10.17 Million and $28.68 Million, respectively
Alabama. BankFirst offers a wide variety of services for businesses and consumers. The Bank also offers internet banking, no-fee ATM access, checking, CD, and money market accounts, merchant services, mortgage loans, remote deposit capture, and more. For more information, visit
More news about: BankFirst Capital Corporation
Jan 30, 2026, 16:30 ET Columbus McKinnon Announces Completion of Senior Secured Notes Offering
offering of the Notes, together with the proceeds from the sale of Series A Cumulative Convertible Participating Preferred Shares of the Company to CD&R XII Keystone Holdings, L.P. and the New Credit Agreement (as defined below), to finance the Acquisition (including the repayment of Kito Crosby's
More news about: Columbus McKinnon Corporation
Jan 30, 2026, 10:36 ET $170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
significance.EPCORE DLBCL-1 is the first Phase 3 study to demonstrate PFS improvement in patients with relapsed/refractory DLBCL treated with a CD3xCD20 T-cell engaging bispecific monotherapy. AbbVie and Genmab will engage global regulatory authorities to discuss next steps while continuing
More news about: Equity Insider
Jan 30, 2026, 08:00 ET Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)
programs (including VIM, ZEB1, FN1);Reduced oncogenic PI3K/AKT and MAPK signalling;Increased intratumoral CD8+ cytotoxic T-cell infiltration and Granzyme B expression; andReduced markers of T-cell exhaustion, including TIM-3 and LAG-3.In
More news about: Kazia Therapeutics Limited
Jan 29, 2026, 14:45 ET Halper Sadeh LLC Encourages SEE, FFWM, ALEX Shareholders to Contact the Firm to Discuss Their Rights
Sealed Air Corporation (NYSE: SEE)'s sale to funds affiliated with CD&R for $42.15 in cash per share. If you are a Sealed Air shareholder,
More news about: Halper Sadeh LLP
Jan 29, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc. - ATRA
with Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy including an anti-CD20 containing regimen." Atara said that "[t]he CRL indicates that the FDA is unable to approve the EBVALLO™ BLA in its present form" because, according
More news about: Pomerantz LLP
Jan 29, 2026, 10:00 ET Hubbell showcases grid automation breakthroughs at DTECH 2026
Resolution Fault Signatures from Synchronized Meter DataDr. David Rieken, VP, Engineering ResearchFeb 4, 11:00–11:50 AM, room 29CDGrid University: Volt/Var Optimization & FLISRDr. Murty Yalla, VP GM, Protection & Control and Robert
More news about: Hubbell Incorporated
Jan 29, 2026, 09:04 ET New Opsera Report Reveals How AI is Transforming Software Delivery and Driving Business Outcomes
emerging agentic tools and IDE-centric assistants are shaping how teams work.Industry Context Matters: Organizations with automated CI/CD pipelines realize greater value from their AI investments, while those with manual workflows face more bottlenecks and rework.Future Challenges:
More news about: Opsera
Jan 29, 2026, 09:00 ET Sony Electronics Evolves Large Display Lineup with the Launch of the BRAVIA Professional Displays BZ-P Series
AI-powered XR signal processing for accurately depicting images, text, and details with realism and vibrancy and offer brightness between 400-700 cd/m2. The full BZ-P Series lineup features a standout Deep Black Non-Glare technology, offering a premium 47%1 or standard 25% anti-glare,
More news about: SONY ELECTRONICS
Jan 28, 2026, 16:00 ET Pacific West Bancorp ("PWBK") Announces Fourth Quarter Financial Results
Investments - CD-
More news about: Pacific West Bancorp
Jan 28, 2026, 09:30 ET Mesh Security Raises $12 Million Series A to Power Autonomous Execution for Cybersecurity Mesh at Enterprise Scale
scale.Over the past decade, organizations invested heavily in best-of-breed stacks across identity, endpoints, data, cloud, SaaS, networks, and CI/CD. While individual tools improved, security as a system did not. The result has been consistent across the industry: too many tools, scattered security
More news about: Mesh Security
Jan 28, 2026, 09:00 ET Adaptive6 emerges from stealth with $44M to detect and remediate cloud waste, bringing the cybersecurity playbook to cloud cost governance
visible waste and "Shadow Waste": hidden inefficiencies that traditional tools miss. Its AI-powered remediation engine integrates directly with Git and CI/CD pipelines, supporting automated Pull Requests and fully automated remediation workflows. Preventative policy enforcement shifts governance left, catching
More news about: Adaptive6
Jan 27, 2026, 15:49 ET DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible
of adult patients with newly diagnosed multiple myeloma (NDMM) who are ineligible for autologous stem cell transplant (ASCT). D-VRd is the only anti-CD38 antibody-based regimen with approved indications across newly diagnosed patients, regardless of transplant eligibility.
More news about: Johnson & Johnson